The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has a low turbidity without good aggregation or particle formation even under accelerated conditions and shows good stability. Therefore, the pharmaceutical preparation can be effectively used for the treatment of disorders such as cancer.本発明は、抗上皮細胞増殖因子受容体(EGFR)抗体を含む医薬製剤を提供する。医薬製剤は、加速条件下でさえ凝集または粒子形成を示すことなく低い濁度を有し、良好な安定性を示す。したがって、医薬製剤は、癌などの障害の処置に効果的に用いられ得る。